{"nctId":"NCT03392974","briefTitle":"Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg","startDateStruct":{"date":"2018-03-14","type":"ACTUAL"},"conditions":["Hemophilia A"],"count":1,"armGroups":[{"label":"Valoctocogene Roxaparvovec Open Label","type":"EXPERIMENTAL","interventionNames":["Biological: Valoctocogene Roxaparvovec"]}],"interventions":[{"name":"Valoctocogene Roxaparvovec","otherNames":["BMN 270"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Males ≥ 18 years of age with hemophilia A and residual FVIII levels ≤ 1 IU/dL as evidenced by medical history.\n2. Must have been on prophylactic FVIII replacement therapy for at least 12 months prior to study entry.\n3. Treated/exposed to FVIII concentrates or cryoprecipitate for a minimum of 150 exposure days.\n4. No previous documented history of a detectable FVIII inhibitor of less than 0.6 Bethesda Units (BU).\n\nExclusion Criteria:\n\n1. Detectable pre-existing antibodies to the AAV5 capsid.\n2. Any evidence of active infection or any immunosuppressive disorder, including HIV infection.\n3. Significant liver dysfunction, prior liver biopsy showing significant fibrosis, liver cirrhosis of any etiology or history of hepatic malignancy.\n4. Evidence of any bleeding disorder not related to hemophilia A.\n5. Active Hepatitis C.\n6. Prior treatment with any vector/gene transfer agent.","healthyVolunteers":false,"sex":"MALE","genderBased":true,"genderDescription":"Biological males only","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change of the Median Factor VIII (FVIII) Activity","description":"Change of the FVIII activity, as measured by chromogenic substrate assay, at Week 52 post-BMN 270 infusion.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Change in the Annualized Utilization (IU/kg) of Exogenous FVIII Replacement Therapy","description":"Change in the annualized utilization (IU/kg) of exogenous FVIII replacement therapy during Week 5 to Week 52 post-BMN 270 infusion from the baseline utilization of exogenous FVIII replacement therapy","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4058.24","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Change in the Annualized Number of Bleeding Episodes Requiring Exogenous FVIII Replacement Treatment","description":"Change in the annualized number of bleeding episodes requiring exogenous FVIII replacement treatment (annualized bleeding rate, ABR) during Week 5 to Week 52 of the study post-BMN 270 infusion from the baseline ABR","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.77","spread":"NA"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":1},"commonTop":["Pyrexia","Hepatocellular injury","Nasopharyngitis","Alanine aminotransferase increased","Myalgia"]}}}